Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 80, Issue 6, pp 1047–1053 | Cite as

The dawn of “immune-revolution” in children: early experiences with checkpoint inhibitors in childhood malignancies

  • Maurizio Lucchesi
  • Iacopo Sardi
  • Gianfranco Puppo
  • Antonio Chella
  • Claudio Favre
Review Article
Part of the following topical collections:
  1. Cytotoxic Reviews

Abstract

Modern immunotherapy with checkpoint inhibitors has changed clinical practice of adult patients with advanced cancer. Blockade of CTLA-4 and PD-1 pathways have shown survival benefits in different diseases. In children, combination of surgery, radiotherapy and chemotherapy have improved survival rates of solid tumors. However, the outcomes for subsets of patients such as those with high-grade, refractory, or metastatic disease remain extremely poor. Currently, the treatment of these patients is almost exclusively based on standard chemotherapy. The significant proportion of pediatric cancers with high number of mutations and subsequent high expression of neoantigens, together with the potential prognostic role of the immunosuppressive checkpoint molecules (CTLA-4, PD-L1) can represent a promising rationale that support the use of checkpoint inhibitors. We made a revision about emerging data regarding safety and activity of checkpoint inhibitors in children with solid tumors.

Keywords

Checkpoint inhibitors Immunotherapy Pediatric solid tumors CTLA-4 PD-1 PD-L1 

Abbreviations

CTLA4

Cytotoxic T lymphocyte antigen 4

PD1

Programmed cell death protein 1

PD-L1

PD-1 ligand 1

NSCLC

Lung cancer

RCC

Renal clear cell carcinoma

HL

Hodgkin’s lymphoma

irAE

Immune-related adverse events

HSCT

Hematologic stem cell transplantation

GVHD

Graft-versus-host disease

bMMRD

Biallelic mismatch repair deficiency

CNS

Central nervous system

Notes

Compliance with ethical standards

Funding

No funding.

Conflict of interest

All authors have no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

References

  1. 1.
    Pandolfi F, Cianci R, Lolli S et al (2008) Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol 21:493–500CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Stewart TJ, Smyth MJ (2011) Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 30:125–140CrossRefPubMedGoogle Scholar
  4. 4.
    Ribas A (2015) Releasing the brakes on cancer immunotherapy. N Engl J Med 373:1490–1492CrossRefPubMedGoogle Scholar
  5. 5.
    Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34CrossRefPubMedGoogle Scholar
  6. 6.
    Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for check-point inhibitor-based immunotherapy. Lancet Oncol 17(12):542–551CrossRefGoogle Scholar
  7. 7.
    Campbell BB, Angelini P, Fabrizio D et al (2017) Large scale tumor mutational burden analysis of pediatric tumors provides a diagnostic tool for germline predisposition and reveals novel candidates for immune checkpoint inhibition. Neuro-Oncology 19(S4):30CrossRefGoogle Scholar
  8. 8.
    Hingorani P, Maas ML, Gustafson MP et al (2015) Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients. J Immunother Cancer 3:35CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chowdhury F, Dunn S, Mitchell S et al (2015) PD-L1 and CD8+ PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. Oncoimmunology 4:e1029701CrossRefGoogle Scholar
  10. 10.
    Kim C, Kim EK, Jung H et al (2016) Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 16:434CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Majzner RG, Simon JS, Grosso JF et al (2015) Assessment of PD-L1 expression and tumor-associated lymphocytes in pediatric cancer tissues. Cancer Res 75:249CrossRefGoogle Scholar
  12. 12.
    Routh JC, Ashley RA, Sebo TJ et al (2008) B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol 179:1954–1959CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Aoki T, Hino M, Koh K et al (2016) Low frequency of programmed death ligand 1 expression in pediatric cancers. Pediatr Blood Cancer 63:1461–1464CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Merchant MS, Wright M, Baird K et al (2016) Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res 22:1364–1370CrossRefPubMedGoogle Scholar
  15. 15.
    Bajčiová V (2015) Therapeutic effect and tolerance of ipilimumab in metastatic malignant melanoma in children—a case report. Klin Onkol 28(Suppl 4):115–120Google Scholar
  16. 16.
    Shad AT, Huo JS, Darcy C et al (2017) Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: a case report. Pediatr Blood Cancer 64(3):e26257CrossRefGoogle Scholar
  17. 17.
    Foran AE, Nadel HR, Lee AF, Savage KJ, Deyell RJ (2016) Nivolumab in the treatment of refractory pediatric Hodgkin lymphoma. J Pediatr Hematol Oncol 39(5):e263–e266CrossRefGoogle Scholar
  18. 18.
    Bouffet E, Larouche V, Campbell BB et al (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206–2211CrossRefPubMedGoogle Scholar
  19. 19.
    Blumenthal DT, Yalon M, Vainer GW et al (2016) Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol 129:453–460CrossRefPubMedGoogle Scholar
  20. 20.
    Barrett D, Fish JD, Grupp S (2010) Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin N Am 57:47–66CrossRefGoogle Scholar
  21. 21.
    Saha A, Aoyama K, Taylor PA et al (2013) Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 122:3062–3073CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Blazar BR, Carreno BM, Panoskaltsis-Mortari A et al (2003) Blockade of programmed death-1 engagement accelerates graft-versus-host dis- ease lethality by an IFN-gamma-dependent mechanism. J Immunol 171:1272–1277CrossRefPubMedGoogle Scholar
  23. 23.
    Gubin MM, Schreiber RD (2015) CANCER: the odds of immunotherapy success. Science 350:158–159CrossRefPubMedGoogle Scholar
  24. 24.
    Zhang J, Walsh MF, Wu G et al (2015) Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373:2336–2346CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Shlien A, Campbell BB, de Borja R et al (2015) Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet 47:257–262CrossRefPubMedGoogle Scholar
  26. 26.
    Durno CA, Aronson M, Tabori U et al (2012) Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer 59:652–656CrossRefPubMedGoogle Scholar
  27. 27.
    Zhu X, McDowell MM, Newman WC et al (2017) Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J Neurosurg Pediatr 19:249–253CrossRefPubMedGoogle Scholar
  28. 28.
    Prins RM, Soto H, Konkankit V et al (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603–1615CrossRefPubMedGoogle Scholar
  29. 29.
    Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534-542CrossRefGoogle Scholar
  30. 30.
    Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691–2697CrossRefPubMedGoogle Scholar
  31. 31.
    Weber JS, Yang JC, Atkins MB et al (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33:2092–2099CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Maurizio Lucchesi
    • 1
    • 4
  • Iacopo Sardi
    • 2
    • 3
    • 4
  • Gianfranco Puppo
    • 1
  • Antonio Chella
    • 1
    • 4
  • Claudio Favre
    • 3
    • 4
  1. 1.Pulmonology Unit, Thoracic Cancer CenterAzienda Ospedaliero-Universitaria PisanaPisaItaly
  2. 2.Neuro-Oncology UnitAnna Meyer Children’s HospitalFlorenceItaly
  3. 3.Department of Pediatric Oncology, Hematology, and TransplantsAnna Meyer Children’s HospitalFlorenceItaly
  4. 4.Tuscany Network for Paediatric Oncology-Istituto Toscano Tumori (ITT)FlorenceItaly

Personalised recommendations